6th May 2015 12:30
NOTIFICATION OF TRANSACTIONS OF DIRECTORS
VERNALIS PLC (the "Company")
6 May 2015
Vernalis plc (LSE: VER) announces it has, today, been informed that Nigel Sheail, Non-Executive Director, bought shares in the Company on 5 May 2015 in London.
Mr Sheail purchased a total of 84,000 ordinary shares of 1 pence each in the Company at an average purchase price of 59.9 pence per share. Mr Sheail is now the beneficial holder of 294,000 ordinary shares of 1 pence each, representing 0.066% of the Company's current issued share capital.
Enquiries:
Vernalis plc: | |
Ian Garland, Chief Executive Officer | +44 (0) 118 938 0015 |
David Mackney, Chief Financial Officer
| |
Canaccord Genuity Limited (Nominated Adviser): | +44 (0) 20 7523 8350 |
Dr Julian Feneley | |
Peter Stewart | |
Pippa Underwood
| |
Shore Capital (Joint Broker): | +44 (0)20 7408 4090 |
Bidhi Bhoma | |
Toby Gibbs
| |
Brunswick Group: | +44 (0) 20 7404 5959 |
Jon Coles |
Notes to Editors
About Vernalis
Vernalis is a revenue generating development stage pharmaceutical company with significant expertise in drug development. The Group has one marketed product, frovatriptan for the acute treatment of migraine, an exclusive licensing agreement to develop and commercialise multiple novel products focussed on the US prescription cough cold market as well as seven programmes in its NCE development pipeline. Vernalis has also significant expertise in fragment and structure based drug discovery which it leverages to enter into collaborations with larger pharmaceutical companies. The Company's technologies, capabilities and products have been endorsed over the last five years by collaborations with leading pharmaceutical companies, including AKP, Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris.
For further information about Vernalis, please visit www.vernalis.com
Related Shares:
Vernalis PLC